Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 25 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR 7 Steps for Developing Microhabits During Cancer That Can Improve Your... November 2, 2023 The Cancer Moonshot: A Midpoint Progress Update January 11, 2021 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Load more HOT NEWS Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival Is a Genomic Test Better at Finding Aggressive Prostate Cancer?
